10.01.2022 23:00:56
|
Pfizer's Omicron-Specific Vaccine To Be Ready In March
(RTTNews) - Pfizer (PFE) CEO Albert Bourla on Monday said that Covid vaccine for omicron variant will be ready in March.
"This vaccine will be ready in March," Bourla told CNBC's Squawk Box. "We [are] already starting manufacturing some of these quantities at risk."
Bourla also said the vaccine will also target the other variants that are circulating.
"The hope is that we will achieve something that will have way, way better protection particularly against infections, because the protection against the hospitalizations and the severe disease — it is reasonable right now, with the current vaccines as long as you are having let's say the third dose," Bourla said.
Meanwhile, Business Insider reported that Pfizer plans to start human testing for its Omicron-specific coronavirus vaccine before the end of January.
"We're going to test that starting now in late January, when we're rolling out clinical trials comparing Omicron towards the current vaccine," said Mikael Dolsten, Pfizer's chief scientific officer.
The Omicron variant is creating havoc across the globe, with several countries reporting a surge in infections and hospitalizations. However, according to Dolsten, it is still not clear that whether a shot specific for Omicron is required or not.
Specifics for this new research are still being finalized with regulators, including how many volunteers will be enrolled and in which countries it'll be conducted, a Pfizer spokesperson said.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.mehr Nachrichten
17.12.24 |
Dienstagshandel in New York: S&P 500 präsentiert sich zum Handelsende leichter (finanzen.at) | |
17.12.24 |
Pfizer-Aktie legt zu: Pfizer prognostiziert für 2025 konstante Umsätze (dpa-AFX) | |
17.12.24 |
Börse New York: S&P 500 liegt nachmittags im Minus (finanzen.at) | |
17.12.24 |
Schwacher Handel: S&P 500 liegt im Minus (finanzen.at) | |
17.12.24 |
S&P 500-Wert Pfizer-Aktie: So viel Verlust hätte eine Pfizer-Investition von vor 10 Jahren eingebracht (finanzen.at) | |
17.12.24 |
NYSE-Handel S&P 500 beginnt die Dienstagssitzung in der Verlustzone (finanzen.at) | |
10.12.24 |
S&P 500-Wert Pfizer-Aktie: So viel Verlust hätte eine Pfizer-Investition von vor 5 Jahren eingebracht (finanzen.at) | |
03.12.24 |
S&P 500-Wert Pfizer-Aktie: So viel hätten Anleger mit einem Investment in Pfizer von vor 3 Jahren verloren (finanzen.at) |
Analysen zu Pfizer Inc.mehr Analysen
19.12.24 | Pfizer Neutral | UBS AG | |
17.12.24 | Pfizer Buy | Jefferies & Company Inc. | |
17.12.24 | Pfizer Neutral | UBS AG | |
17.12.24 | Pfizer Neutral | JP Morgan Chase & Co. | |
12.12.24 | Pfizer Neutral | JP Morgan Chase & Co. |